

**Experiment Number:** 20108-04  
**Test Type:** 90-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/TRAMP

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

**Test Compound:** Antioxidant model (TRAMP) - Epigallocatechin gallate  
**CAS Number:** 989-51-5

**Date Report Requested:** 10/23/2014  
**Time Report Requested:** 09:14:27  
**First Dose M/F:** NA / NA  
**Lab:** ILS

|                             |              |
|-----------------------------|--------------|
| <b>C Number:</b>            | C20108B      |
| <b>Lock Date:</b>           | Not Entered. |
| <b>Cage Range:</b>          | All          |
| <b>Date Range:</b>          | All          |
| <b>Reasons For Removal:</b> | All          |
| <b>Removal Date Range:</b>  | All          |
| <b>Treatment Groups:</b>    | All          |
| <b>Study Gender:</b>        | Male         |
| <b>PWG Approval Date</b>    | NONE         |

Experiment Number: 20108-04

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Mouse/TRAMP

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

Test Compound: Antioxidant model (TRAMP) - Epigallocatechin gallate

CAS Number: 989-51-5

Date Report Requested: 10/23/2014

Time Report Requested: 09:14:27

First Dose M/F: NA / NA

Lab: ILS

| TRAMP Mouse MALE                 | VEHICLE CONTROL | EGCG | 200MG/KG |
|----------------------------------|-----------------|------|----------|
| <b>Disposition Summary</b>       |                 |      |          |
| Animals Initially In Study       | 10              |      | 32       |
| Scheduled Sacrifice              | 10              |      | 32       |
| Early Deaths                     |                 |      |          |
| Survivors                        |                 |      |          |
| Animals Examined Microscopically | 10              |      | 32       |
| <b>ALIMENTARY SYSTEM</b>         |                 |      |          |
| Liver                            | (10)            |      | (32)     |
| <b>CARDIOVASCULAR SYSTEM</b>     |                 |      |          |
| None                             |                 |      |          |
| <b>ENDOCRINE SYSTEM</b>          |                 |      |          |
| Pituitary Gland                  | (9)             |      | (26)     |
| <b>GENERAL BODY SYSTEM</b>       |                 |      |          |
| None                             |                 |      |          |
| <b>GENITAL SYSTEM</b>            |                 |      |          |
| Epididymis                       | (10)            |      | (31)     |
| Prostate                         | (2)             |      | (0)      |
| Carcinoma                        | 2 (100%)        |      |          |
| Prostate, Anterior Lobe          | (10)            |      | (32)     |
| Prostate, Dorsal Lobe            | (9)             |      | (32)     |
| Prostate, Lateral Lobe           | (6)             |      | (31)     |
| Carcinoma                        | 1 (17%)         |      |          |
| Prostate, Ventral Lobe           | (8)             |      | (23)     |
| Carcinoma                        | 1 (13%)         |      | 1 (4%)   |
| Seminal Vesicle                  | (10)            |      | (32)     |
| Testes                           | (10)            |      | (32)     |

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

**Experiment Number:** 20108-04  
**Test Type:** 90-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/TRAMP

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

**Test Compound:** Antioxidant model (TRAMP) - Epigallocatechin gallate  
**CAS Number:** 989-51-5

**Date Report Requested:** 10/23/2014  
**Time Report Requested:** 09:14:27  
**First Dose M/F:** NA / NA  
**Lab:** ILS

| TRAMP Mouse MALE       | VEHICLE CONTROL | EGCG | 200MG/KG |
|------------------------|-----------------|------|----------|
| HEMATOPOIETIC SYSTEM   |                 |      |          |
| Spleen                 | (10)            |      | (31)     |
| INTEGUMENTARY SYSTEM   |                 |      |          |
| None                   |                 |      |          |
| MUSCULOSKELETAL SYSTEM |                 |      |          |
| None                   |                 |      |          |
| NERVOUS SYSTEM         |                 |      |          |
| None                   |                 |      |          |
| RESPIRATORY SYSTEM     |                 |      |          |
| None                   |                 |      |          |
| SPECIAL SENSES SYSTEM  |                 |      |          |
| Eye                    | (1)             |      | (0)      |
| URINARY SYSTEM         |                 |      |          |
| Kidney                 | (10)            |      | (32)     |
| Urinary Bladder        | (10)            |      | (26)     |

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

**Experiment Number:** 20108-04  
**Test Type:** 90-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/TRAMP

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

**Test Compound:** Antioxidant model (TRAMP) - Epigallocatechin gallate  
**CAS Number:** 989-51-5

**Date Report Requested:** 10/23/2014  
**Time Report Requested:** 09:14:27  
**First Dose M/F:** NA / NA  
**Lab:** ILS

---

| <b>TRAMP Mouse MALE</b>  | <b>VEHICLE CONTROL</b> | <b>EGCG</b> | <b>200MG/KG</b> |
|--|------------------------|-------------|-----------------|
| <b>Tumor Summary for MALE</b>  |                        |             |                 |
| <b>Total Animals with Primary Neoplasms (b)</b>                          | <b>4</b>               |             | <b>1</b>        |
| <b>Total Primary Neoplasms</b>   | <b>4</b>               |             | <b>1</b>        |
| <b>Total Animals with Benign Neoplasms</b>                               |                        |             |                 |
| <b>Total Benign Neoplasms</b>  |                        |             |                 |
| <b>Total Animals with Malignant Neoplasms</b>                            | <b>4</b>               |             | <b>1</b>        |
| <b>Total Malignant Neoplasms</b>   | <b>4</b>               |             | <b>1</b>        |
| <b>Total Animals with Metastatic Neoplasms</b>                           |                        |             |                 |
| <b>Total Metastatic Neoplasms</b>  |                        |             |                 |
| <b>Total Animals with Malignant Neoplasms<br/>Uncertain Primary Site</b> |                        |             |                 |
| <b>Total Animals with Neoplasms Uncertain -<br/>Benign or Malignant</b>  |                        |             |                 |
| <b>Total Uncertain Neoplasms</b>   |                        |             |                 |

---

**\*\* END OF REPORT \*\***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically